FDA Evaluating The Need For Regulatory Action In Argenx's Vyvgart Hytrulo After Reports Of Severe Worsening Of Chronic Inflammatory Demyelinating Polyradiculoneuropathy In CIDP Patients

Benzinga · 06/30 15:39